<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01156571</url>
  </required_header>
  <id_info>
    <org_study_id>TMC-CAN-10-01</org_study_id>
    <nct_id>NCT01156571</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)</brief_title>
  <acronym>CHAMPION</acronym>
  <official_title>A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <brief_summary>
    <textblock>
      The study is designed to compare the efficacy and safety profile of cangrelor to standard of
      care in patients require percutaneous coronary intervention (PCI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)</measure>
    <time_frame>48 hours after randomization</time_frame>
    <description>Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)</measure>
    <time_frame>48 hours after randomization</time_frame>
    <description>CEC-adjudicated results (mITT population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild</measure>
    <time_frame>48 hours after randomization</time_frame>
    <description>GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11145</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>cangrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.
Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion.
During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cangrelor P2Y12 (platelet) inhibitor</intervention_name>
    <arm_group_label>cangrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel - 300 or 600 mg (study arm)</intervention_name>
    <description>Over encapsulated tablets.</description>
    <arm_group_label>clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 600 mg post cangrelor</intervention_name>
    <description>over-encapsulated clopidogrel (600 mg)</description>
    <arm_group_label>cangrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients may be included in the study if they meet all of the following criteria:

          -  Male or non-pregnant female at least 18 years of age

          -  Patients undergoing percutaneous coronary intervention (PCI):

               1. Stable angina (SA) patients with diagnostic coronary angiography within 90 days
                  prior to randomization demonstrating atherosclerosis

               2. Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) patients with
                  diagnostic coronary angiography within 72 hours prior to randomization
                  demonstrating atherosclerosis

               3. ST-segment elevation myocardial infarction (STEMI) patients (diagnostic
                  angiography not required)

          -  Provide written informed consent

        Exclusion Criteria:

        Patients will be excluded from the study if any of the following exclusion criteria apply
        prior to randomization:

          -  Receipt of any P2Y12 inhibitor at any time in the 7 days preceding randomization

          -  Eptifibatide and tirofiban usage within 12 hours preceding randomization (most recent
             dose must have been administered ≥12 hours prior to randomization)

          -  Abciximab usage within 7 days preceding randomization

          -  Receipt of fibrinolytic therapy in the 12 hours preceding randomization

          -  Increased bleeding risk: ischemic stroke within the last year or any previous
             hemorrhagic stroke; tumor, cerebral arteriovenous malformation, or intracranial
             aneurysm; recent (&lt;1 month) trauma or major surgery (including bypass surgery);
             currently receiving warfarin; active bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anderson Area Medical Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>July 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 5, 2010</study_first_posted>
  <results_first_submitted>April 22, 2013</results_first_submitted>
  <results_first_submitted_qc>April 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 18, 2013</results_first_posted>
  <last_update_submitted>January 2, 2014</last_update_submitted>
  <last_update_submitted_qc>January 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Cangrelor</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date first patient enrolled: 30 Sep 2010 Date last patient completed: 14 Nov 2012
This trial enrolled the full spectrum of patients who required PCI (SA, NSTE-ACS, STEMI). Randomization occurred after confirmation of need for PCI (after diagnostic angiogram in all cases, except for STEMI patients). Patients were followed through 30-days.</recruitment_details>
      <pre_assignment_details>Due to the nature of the disease, STEMI patients were permitted to be randomized upon ECG confirmation and prior to confirmation of need for PCI (prior to diagnostic angiography). Therefore in some cases, STEMI patients did not require PCI and therefore did not receive all study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cangrelor Treatment Arm</title>
          <description>Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.
Immediately after discontinuation of infusion, an oral transition dose of clopidogrel 600 mg was administered.
Patients also received oral placebo capsules, administered as soon as possible following randomization at investigator discretion. These capsules were designed to match the clopidogrel 600 mg or 300 mg loading dose.</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel Treatment Arm</title>
          <description>Oral clopidogrel was administered as soon as possible following randomization at investigator discretion at a loading dose of either 600 mg or 300 mg as specified by the investigator.
Patients in the clopidogrel treatment arm received IV placebo for 2 hours or end of the PCI procedure, whichever was longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.
At the end of IV placebo infusion, patients were given oral placebo capsules matching the oral clopidogrel transition dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5581">ITT: defined as all patients randomized.</participants>
                <participants group_id="P2" count="5564">ITT: defined as all patients randomized.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5564">Completed = ITT patients who completed scheduled visits or developed a primary endpoint event</participants>
                <participants group_id="P2" count="5545">Completed = ITT patients who completed scheduled visits or developed a primary endpoint event</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Cangrelor Treatment Arm</title>
          <description>Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.
Immediately after discontinuation of infusion, an oral transition dose of clopidogrel 600 mg was administered.
Patients also received oral placebo capsules, administered as soon as possible following randomization at investigator discretion. These capsules were designed to match the clopidogrel 600 mg or 300 mg loading dose.</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel Treatment Arm</title>
          <description>Oral clopidogrel was administered as soon as possible following randomization at investigator discretion at a loading dose of either 600 mg or 300 mg as specified by the investigator.
Patients in the clopidogrel treatment arm received IV placebo for 2 hours or end of the PCI procedure, whichever was longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.
At the end of IV placebo infusion, patients were given oral placebo capsules matching the oral clopidogrel transition dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5581"/>
            <count group_id="B2" value="5564"/>
            <count group_id="B3" value="11145"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2892"/>
                    <measurement group_id="B2" value="2902"/>
                    <measurement group_id="B3" value="5794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2689"/>
                    <measurement group_id="B2" value="2662"/>
                    <measurement group_id="B3" value="5351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="11.0"/>
                    <measurement group_id="B2" value="63.8" spread="11.0"/>
                    <measurement group_id="B3" value="63.9" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1599"/>
                    <measurement group_id="B2" value="1522"/>
                    <measurement group_id="B3" value="3121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3982"/>
                    <measurement group_id="B2" value="4042"/>
                    <measurement group_id="B3" value="8024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2099"/>
                    <measurement group_id="B2" value="2089"/>
                    <measurement group_id="B3" value="4188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="814"/>
                    <measurement group_id="B2" value="816"/>
                    <measurement group_id="B3" value="1630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="744"/>
                    <measurement group_id="B2" value="741"/>
                    <measurement group_id="B3" value="1485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="251"/>
                    <measurement group_id="B3" value="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="311"/>
                    <measurement group_id="B2" value="310"/>
                    <measurement group_id="B3" value="621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="352"/>
                    <measurement group_id="B2" value="350"/>
                    <measurement group_id="B3" value="702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="296"/>
                    <measurement group_id="B2" value="286"/>
                    <measurement group_id="B3" value="582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)</title>
        <description>Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population)</description>
        <time_frame>48 hours after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor Treatment Arm</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel Treatment Arm</title>
          </group>
        </group_list>
        <measure>
          <title>The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)</title>
          <description>Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5470"/>
                <count group_id="O2" value="5469"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)</title>
        <description>CEC-adjudicated results (mITT population)</description>
        <time_frame>48 hours after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor Treatment Arm</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel Treatment Arm</title>
          </group>
        </group_list>
        <measure>
          <title>Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)</title>
          <description>CEC-adjudicated results (mITT population)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5470"/>
                <count group_id="O2" value="5469"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stent Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MI (myocardial infarction)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IDR (ischemia-driven revascularization)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild</title>
        <description>GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial</description>
        <time_frame>48 hours after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cangrelor Treatment Arm</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel Treatment Arm</title>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild</title>
          <description>GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5529"/>
                <count group_id="O2" value="5527"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GUSTO severe/life threatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GUSTO moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GUSTO severe or moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI major or minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any blood transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and SAEs were collected from the time of randomization until 48 hours after randomization. If there was a delay between randomization and study drug initiation, AEs were collected from randomization through 48 hours after study drug initiation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cangrelor Treatment Arm</title>
        </group>
        <group group_id="E2">
          <title>Clopidogrel Treatment Arm</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>Hypersplenism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>coronary artery performation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>Interventricluar septum rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>mycardial rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>percarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>ventricular rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>ventricular asystole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>ventricluar tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>small intestine gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>cardiac procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>medication error</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>electrocardiogram ST segment elevation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>arterial rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5527"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5527"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In general, PI communications regarding trial results are prohibited until after the communication and publication of the multi-center results by Sponsor, but no more than 12 months after conclusion of the trial at all sites.
PI must submit results communications to sponsor for review at least 45 days prior to submission for publication and Sponsor may embargo such communications for a period that is less than or equal to 135 days solely to seek appropriate patent protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Meredith Todd - Sr. Director Program Management</name_or_title>
      <organization>The Medicines Company</organization>
      <phone>+1.973.290.6088</phone>
      <email>meredith.todd@themedco.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

